$BLCO

Munsch Frederick sold $888K of BLCO

Munsch Frederick (SVP, Controller and CAO) sold 52,900 shares of Bausch & Lomb Corp (BLCO) at $16.78 ($0.89M total) on 2026-08-10.

Original reporting
SEC EDGAR · Munsch Frederick
Published Aug 12, 2026, 11:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 11:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLCO
Neutral
medium confidence
Mentioned
$BLCO
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLCONeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider selling activity (shares, price, total value, post-transaction holdings) but no new operational or strategic information.

02

Market read

Traders may briefly reassess sentiment around BLCO due to insider selling, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

No 10b5-1 plan is cited, but the filing also lacks motivation, option exercises, or other concurrent insider activity that would help interpret intent.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-12, sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for Bausch & Lomb Corp.

Company-level read

Ticker impact

$BLCONeutralMedium confidence
Context

Bausch & Lomb insider Munsch Frederick sold 52,900 shares at $16.7800 on 2026-08-10, totaling $887,662, per Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment.

Evidence & confidence

The filing discloses transaction size and price but provides no new company-specific operating or regulatory information. Insider sales are common and often not predictive, especially without additional context.

Market effects

Minimal. Insider sale does not change sector fundamentals for eye care/pharma peers based on the provided text.

None indicated.

None indicated.

Counterpoint

The sale could be driven by diversification, taxes, or pre-existing personal liquidity needs, so it may not signal reduced confidence in BLCO’s outlook.

Key entities

  • Bausch & Lomb Corp

    Subject of the Form 4 insider transaction disclosure.

  • Munsch Frederick

    SVP, Controller and CAO who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BLCOMedAI 8/10

What Bausch + Lomb (BLCO) Said on Its Q3 Earnings Call

Bausch + Lomb (BLCO) reported Q3 earnings, highlighting growth across multiple franchises. Adjusted gross margin rose to 64.7%, with operating cash flow at $233M. The company raised its 2026 revenue outlook to $5.45B-$5.55B and adjusted EBITDA guidance to $1.09B-$1.14B. Interim CEO Appio focused on profitability and R&D pipeline advancements.

$BLCOHighAI 8/10

Bausch & Lomb Corp (BLCO) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth

Bausch & Lomb Corp (BLCO) reported Q3 2026 revenue growth of 8%, with all segments showing gains. Adjusted EBITDA rose 34% to $325M. The company raised full-year revenue and EBITDA guidance. Key products like MIBO and Lumify saw strong growth, while surgical equipment revenue declined 11%. The company faces regulatory and competitive pressures. Leadership changes were announced, with Tom Appio becoming interim CEO.

$BLCOHighAI 8/10

Bausch + Lomb Soars 16% on Big Q3 Profit Beat and Raised Full-Year Guidance

Bausch + Lomb's shares rose 16% after Q3 earnings beat expectations, with adjusted EPS at $0.34 vs. $0.22 consensus and revenue up 7% to $1.375B. Adjusted EBITDA increased 34% to $325M, and the company raised its full-year EBITDA guidance by $65M. Key growth drivers included MIEBO, LUMIFY, and premium intraocular lenses. Johnson & Johnson's contact lens sales also grew, contrasting with Cooper Companies' flat sales.

$BLCOMed

Bausch + Lomb: Q3 Earnings Snapshot

Bausch + Lomb (BLCO) reported Q3 net income of $32M, or 9 cents per share, beating estimates. Adjusted EPS was 34 cents. Revenue was $1.38B, also topping forecasts. The company expects full-year revenue of $5.45B-$5.55B. Shares are up 14% YTD and 26% over 12 months.